NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
Clinical Trials
16 trialsNCT04469556 2026-02-20
PASS-01
University Health Network, Toronto
Phase 2 Completed
NCT00208260 2026-02-05
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2/3 Completed
NCT02352337 2024-07-10
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT01827553 2024-04-11
CONKO-007
University of Erlangen-Nürnberg Medical School
Phase 3 Completed
NCT02128100 2024-03-05
BCC-RAD-13
University of Louisville
Phase 2 Completed
NCT03914170 2023-09-26
ESTER
Institut du Cancer de Montpellier - Val d'Aurelle
Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT04990037 2023-06-29
CAPAFOUR
Cantargia AB
Phase 1 Completed
NCT03504423 2023-01-03
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals
Phase 3 Completed
NCT02873598 2022-12-19
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
University of Colorado, Denver
Phase 1 Completed
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02456714 2020-03-10
4CC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT01523457 2017-08-30
FOLFIRINOX
Yale University
Phase 2 Completed
NCT01383538 2017-08-08
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT01488552 2016-08-18
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer Research Team
Phase 1/2 Completed